NYSE:WST

West Pharmaceutical Services Competitors

$300.06
-6.39 (-2.09 %)
(As of 04/14/2021 04:37 PM ET)
Add
Compare
Today's Range
$298.94
Now: $300.06
$307.46
50-Day Range
$257.29
MA: $278.48
$296.94
52-Week Range
$163.76
Now: $300.06
$312.12
Volume421,567 shs
Average Volume470,472 shs
Market Capitalization$22.16 billion
P/E Ratio79.17
Dividend Yield0.23%
Beta1.13

Competitors

West Pharmaceutical Services (NYSE:WST) Vs. ALGN, COO, XRAY, HAE, QDEL, and STAA

Should you be buying WST stock or one of its competitors? Companies in the sub-industry of "health care supplies" are considered alternatives and competitors to West Pharmaceutical Services, including Align Technology (ALGN), The Cooper Companies (COO), DENTSPLY SIRONA (XRAY), Haemonetics (HAE), Quidel (QDEL), and STAAR Surgical (STAA).

West Pharmaceutical Services (NYSE:WST) and Align Technology (NASDAQ:ALGN) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Risk & Volatility

West Pharmaceutical Services has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, Align Technology has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for West Pharmaceutical Services and Align Technology, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
West Pharmaceutical Services01202.67
Align Technology13902.62

West Pharmaceutical Services currently has a consensus target price of $310.00, suggesting a potential upside of 3.31%. Align Technology has a consensus target price of $501.3333, suggesting a potential downside of 15.71%. Given West Pharmaceutical Services' stronger consensus rating and higher probable upside, analysts clearly believe West Pharmaceutical Services is more favorable than Align Technology.

Valuation and Earnings

This table compares West Pharmaceutical Services and Align Technology's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
West Pharmaceutical Services$1.84 billion12.04$241.70 million$3.2492.61
Align Technology$2.41 billion19.56$442.78 million$4.96119.95

Align Technology has higher revenue and earnings than West Pharmaceutical Services. West Pharmaceutical Services is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

92.6% of West Pharmaceutical Services shares are owned by institutional investors. Comparatively, 85.8% of Align Technology shares are owned by institutional investors. 1.6% of West Pharmaceutical Services shares are owned by company insiders. Comparatively, 1.2% of Align Technology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares West Pharmaceutical Services and Align Technology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
West Pharmaceutical Services14.69%19.01%12.78%
Align Technology76.00%68.99%46.64%

Summary

Align Technology beats West Pharmaceutical Services on 9 of the 14 factors compared between the two stocks.

West Pharmaceutical Services (NYSE:WST) and The Cooper Companies (NYSE:COO) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Risk and Volatility

West Pharmaceutical Services has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, The Cooper Companies has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for West Pharmaceutical Services and The Cooper Companies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
West Pharmaceutical Services01202.67
The Cooper Companies04602.60

West Pharmaceutical Services currently has a consensus target price of $310.00, suggesting a potential upside of 3.31%. The Cooper Companies has a consensus target price of $384.25, suggesting a potential downside of 1.68%. Given West Pharmaceutical Services' stronger consensus rating and higher probable upside, analysts clearly believe West Pharmaceutical Services is more favorable than The Cooper Companies.

Earnings and Valuation

This table compares West Pharmaceutical Services and The Cooper Companies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
West Pharmaceutical Services$1.84 billion12.04$241.70 million$3.2492.61
The Cooper Companies$2.43 billion7.91$238.40 million$9.6440.57

West Pharmaceutical Services has higher earnings, but lower revenue than The Cooper Companies. The Cooper Companies is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Dividends

West Pharmaceutical Services pays an annual dividend of $0.68 per share and has a dividend yield of 0.2%. The Cooper Companies pays an annual dividend of $0.06 per share and has a dividend yield of 0.0%. West Pharmaceutical Services pays out 21.0% of its earnings in the form of a dividend. The Cooper Companies pays out 0.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. West Pharmaceutical Services has increased its dividend for 25 consecutive years and The Cooper Companies has increased its dividend for 1 consecutive years. West Pharmaceutical Services is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Institutional and Insider Ownership

92.6% of West Pharmaceutical Services shares are owned by institutional investors. Comparatively, 95.8% of The Cooper Companies shares are owned by institutional investors. 1.6% of West Pharmaceutical Services shares are owned by company insiders. Comparatively, 1.4% of The Cooper Companies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares West Pharmaceutical Services and The Cooper Companies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
West Pharmaceutical Services14.69%19.01%12.78%
The Cooper Companies9.81%12.79%7.20%

Summary

West Pharmaceutical Services beats The Cooper Companies on 11 of the 17 factors compared between the two stocks.

West Pharmaceutical Services (NYSE:WST) and DENTSPLY SIRONA (NASDAQ:XRAY) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Dividends

West Pharmaceutical Services pays an annual dividend of $0.68 per share and has a dividend yield of 0.2%. DENTSPLY SIRONA pays an annual dividend of $0.40 per share and has a dividend yield of 0.6%. West Pharmaceutical Services pays out 21.0% of its earnings in the form of a dividend. DENTSPLY SIRONA pays out 16.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. West Pharmaceutical Services has increased its dividend for 25 consecutive years and DENTSPLY SIRONA has increased its dividend for 1 consecutive years. DENTSPLY SIRONA is clearly the better dividend stock, given its higher yield and lower payout ratio.

Earnings and Valuation

This table compares West Pharmaceutical Services and DENTSPLY SIRONA's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
West Pharmaceutical Services$1.84 billion12.04$241.70 million$3.2492.61
DENTSPLY SIRONA$4.03 billion3.55$262.90 million$2.4526.62

DENTSPLY SIRONA has higher revenue and earnings than West Pharmaceutical Services. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for West Pharmaceutical Services and DENTSPLY SIRONA, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
West Pharmaceutical Services01202.67
DENTSPLY SIRONA15702.46

West Pharmaceutical Services currently has a consensus target price of $310.00, suggesting a potential upside of 3.31%. DENTSPLY SIRONA has a consensus target price of $55.3333, suggesting a potential downside of 15.12%. Given West Pharmaceutical Services' stronger consensus rating and higher probable upside, analysts clearly believe West Pharmaceutical Services is more favorable than DENTSPLY SIRONA.

Risk and Volatility

West Pharmaceutical Services has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, DENTSPLY SIRONA has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500.

Profitability

This table compares West Pharmaceutical Services and DENTSPLY SIRONA's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
West Pharmaceutical Services14.69%19.01%12.78%
DENTSPLY SIRONA-1.40%7.13%4.13%

Institutional and Insider Ownership

92.6% of West Pharmaceutical Services shares are owned by institutional investors. Comparatively, 96.0% of DENTSPLY SIRONA shares are owned by institutional investors. 1.6% of West Pharmaceutical Services shares are owned by company insiders. Comparatively, 0.5% of DENTSPLY SIRONA shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

West Pharmaceutical Services beats DENTSPLY SIRONA on 11 of the 17 factors compared between the two stocks.

Haemonetics (NYSE:HAE) and West Pharmaceutical Services (NYSE:WST) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, earnings and profitability.

Earnings and Valuation

This table compares Haemonetics and West Pharmaceutical Services' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Haemonetics$988.48 million6.01$76.53 million$3.3135.32
West Pharmaceutical Services$1.84 billion12.04$241.70 million$3.2492.61

West Pharmaceutical Services has higher revenue and earnings than Haemonetics. Haemonetics is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Haemonetics and West Pharmaceutical Services, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Haemonetics00403.00
West Pharmaceutical Services01202.67

Haemonetics presently has a consensus price target of $144.80, suggesting a potential upside of 23.63%. West Pharmaceutical Services has a consensus price target of $310.00, suggesting a potential upside of 3.31%. Given Haemonetics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Haemonetics is more favorable than West Pharmaceutical Services.

Volatility and Risk

Haemonetics has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Comparatively, West Pharmaceutical Services has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500.

Profitability

This table compares Haemonetics and West Pharmaceutical Services' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Haemonetics11.76%22.85%10.40%
West Pharmaceutical Services14.69%19.01%12.78%

Insider and Institutional Ownership

96.2% of Haemonetics shares are owned by institutional investors. Comparatively, 92.6% of West Pharmaceutical Services shares are owned by institutional investors. 1.6% of Haemonetics shares are owned by insiders. Comparatively, 1.6% of West Pharmaceutical Services shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Quidel (NASDAQ:QDEL) and West Pharmaceutical Services (NYSE:WST) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, earnings and profitability.

Volatility and Risk

Quidel has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500. Comparatively, West Pharmaceutical Services has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500.

Earnings and Valuation

This table compares Quidel and West Pharmaceutical Services' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quidel$534.89 million10.23$72.92 million$2.7347.34
West Pharmaceutical Services$1.84 billion12.04$241.70 million$3.2492.61

West Pharmaceutical Services has higher revenue and earnings than Quidel. Quidel is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

84.0% of Quidel shares are owned by institutional investors. Comparatively, 92.6% of West Pharmaceutical Services shares are owned by institutional investors. 14.1% of Quidel shares are owned by insiders. Comparatively, 1.6% of West Pharmaceutical Services shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Quidel and West Pharmaceutical Services, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quidel10302.50
West Pharmaceutical Services01202.67

Quidel presently has a consensus price target of $262.75, suggesting a potential upside of 103.54%. West Pharmaceutical Services has a consensus price target of $310.00, suggesting a potential upside of 3.31%. Given Quidel's higher probable upside, equities research analysts clearly believe Quidel is more favorable than West Pharmaceutical Services.

Profitability

This table compares Quidel and West Pharmaceutical Services' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quidel36.91%63.31%40.55%
West Pharmaceutical Services14.69%19.01%12.78%

Summary

West Pharmaceutical Services beats Quidel on 8 of the 14 factors compared between the two stocks.

STAAR Surgical (NASDAQ:STAA) and West Pharmaceutical Services (NYSE:WST) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

Valuation and Earnings

This table compares STAAR Surgical and West Pharmaceutical Services' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
STAAR Surgical$150.18 million36.28$14.05 million$0.46254.39
West Pharmaceutical Services$1.84 billion12.04$241.70 million$3.2492.61

West Pharmaceutical Services has higher revenue and earnings than STAAR Surgical. West Pharmaceutical Services is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

STAAR Surgical has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, West Pharmaceutical Services has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for STAAR Surgical and West Pharmaceutical Services, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
STAAR Surgical03302.50
West Pharmaceutical Services01202.67

STAAR Surgical presently has a consensus price target of $68.50, suggesting a potential downside of 41.46%. West Pharmaceutical Services has a consensus price target of $310.00, suggesting a potential upside of 3.31%. Given West Pharmaceutical Services' stronger consensus rating and higher probable upside, analysts plainly believe West Pharmaceutical Services is more favorable than STAAR Surgical.

Profitability

This table compares STAAR Surgical and West Pharmaceutical Services' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
STAAR Surgical5.73%8.99%7.12%
West Pharmaceutical Services14.69%19.01%12.78%

Insider & Institutional Ownership

85.4% of STAAR Surgical shares are owned by institutional investors. Comparatively, 92.6% of West Pharmaceutical Services shares are owned by institutional investors. 3.9% of STAAR Surgical shares are owned by insiders. Comparatively, 1.6% of West Pharmaceutical Services shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

West Pharmaceutical Services beats STAAR Surgical on 10 of the 14 factors compared between the two stocks.


West Pharmaceutical Services Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Align Technology logo
ALGN
Align Technology
1.9$594.93-0.1%$47.08 billion$2.41 billion27.07
The Cooper Companies logo
COO
The Cooper Companies
1.9$391.05-0.0%$19.21 billion$2.43 billion81.30
DENTSPLY SIRONA logo
XRAY
DENTSPLY SIRONA
2.0$65.22-2.1%$13.99 billion$4.03 billion-283.57Decrease in Short Interest
Haemonetics logo
HAE
Haemonetics
1.6$116.91-0.6%$5.97 billion$988.48 million56.48
Quidel logo
QDEL
Quidel
2.4$129.24-0.3%$5.47 billion$534.89 million15.17
STAAR Surgical logo
STAA
STAAR Surgical
1.4$117.02-1.2%$5.45 billion$150.18 million615.93Increase in Short Interest
Neogen logo
NEOG
Neogen
1.2$94.23-1.0%$4.99 billion$418.17 million82.66
ICU Medical logo
ICUI
ICU Medical
1.5$205.63-0.2%$4.37 billion$1.27 billion54.40Insider Selling
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.5$61.40-0.7%$3.39 billion$994.85 million-115.85
Atrion logo
ATRI
Atrion
1.1$645.51-0.1%$1.18 billion$155.07 million36.37
Cerus logo
CERS
Cerus
1.7$6.22-0.6%$1.05 billion$74.65 million-15.95News Coverage
Meridian Bioscience logo
VIVO
Meridian Bioscience
1.7$23.94-1.4%$1.05 billion$253.67 million22.17
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.26-0.6%$742.48 million$154.60 million-44.61
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.06-0.5%$679.37 million$123.86 million67.68
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$40.96-1.3%$586.96 million$114.51 million-87.15Gap Down
Utah Medical Products logo
UTMD
Utah Medical Products
0.9$87.99-0.9%$317.93 million$46.90 million27.76
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.